Antibody responses in patients with invasive Staphylococcus aureus infections
- 10 April 2010
- journal article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 29 (6), 715-725
- https://doi.org/10.1007/s10096-010-0919-x
Abstract
Correlation between antibody response and clinical outcome in Staphylococcus aureus bacteremia has yielded conflicting results. Immunization schedules have failed in clinical trials. Is the humoral response toward S. aureus of protective nature? A prospective study was performed in patients with invasive S. aureus (ISA) infections during the period 2003–2005. The antibody levels were determined at the beginning and at the end of treatment and one month later (n = 96, n = 71, and n = 51, respectively). As controls, 115 healthy individuals were used. A quantitative enzyme-linked immunosorbent assay (ELISA) against eight purified antigens was performed. Bacterial isolates were grouped as to the production of alpha-toxin, agr type, and pulsed-field gel electrophoresis (PFGE) type. Large variations were seen in the antibody levels. The levels in the second sample were the highest. A correlation between agr group, PFGE group, alpha-toxin production, and initial antibody levels was observed. Patients with fatal outcome displayed lower initial antibody levels to all antigens and significantly so in regard to teichoic acid, lipase, enterotoxin A, and scalded skin syndrome toxin. In episodes with complicated bacteremia, initial significantly low levels to teichoic acid and lipase were registered. Low initial antibody levels against several antigens were associated with increased mortality and complicated bacteremia in invasive S. aureus infections. Bacterial properties, strain, and toxin production affected the antibody response.Keywords
This publication has 47 references indexed in Scilit:
- Pediatric Antibody Response to Community-Acquired Staphylococcus aureus Infection Is Directed to Panton-Valentine LeukocidinClinical and Vaccine Immunology, 2009
- Vaccine protection againstStaphylococcus aureuspneumoniaThe Journal of Experimental Medicine, 2008
- Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive powerCurrent Opinion in Microbiology, 2007
- Clinical Trial of Safety and Efficacy of IHN-A21 for the Prevention of Nosocomial Staphylococcal Bloodstream Infection in Premature InfantsThe Journal of Pediatrics, 2007
- Intermediate Vancomycin Susceptibility in a Community-associated MRSA CloneEmerging Infectious Diseases, 2007
- The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western SwedenScandinavian Journal of Infectious Diseases, 2007
- Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected PatientsClinical and Vaccine Immunology, 2005
- Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving HemodialysisNew England Journal of Medicine, 2002
- Distinguishing Complicated from Uncomplicated Bacteremia Caused by Staphylococcus aureus: The Value of "New" and "Old" Serological TestsThe Journal of Infectious Diseases, 1986
- Antibody responses to Staphylococcus aureus cell wall antigensClinical Immunology Newsletter, 1985